You are here: Home:  CCU 2 | 2004: Richard M Goldberg, MD: Select publications


Select publications

Alberts SR et al. Oxaliplatin (OXAL), 5-fluorouracil (5FU), and leucovorin (CF) for patients (pts) with liver only metastases (mets) from colorectal cancer (CRC): A North Central Cancer Treatment Group (NCCTG) phase II study. Proc ASCO 2003;Abstract 1053.

Andre T et al. FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study. Proc ASCO 2003;Abstract 1016.

Cunningham D et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc ASCO 2003;Abstract 1012.

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc ASCO 2003;Abstract 1015.

Goldberg RM et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23-30. Abstract

Saltz L et al. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc ASCO 2002;Abstract 504.

Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22(2):229-37. Abstract

 

Table of Contents Top of Page

Home

Editor’s Note:
Rounds with the professors
 
Richard M Goldberg, MD
- Select publications
 
Axel Grothey, MD
- Select publications
 
Heinz-Josef Lenz, MD, FACP
- Select publications
 

Faculty Disclosures

A CME Audio Series
and Activity

Editor's office

 

Terms of use and general disclaimer
© Research To Practice, 2004. All rights reserved.